Sign in
Taking peoplePhase 2

Serotonin receptors and impulsivity in adults with Tourette syndrome

Studies how serotonin receptors relate to impulsivity in adults with Tourette syndrome.

Key facts

Who runs it
Hospices Civils De Lyon
Where
France1 site in 1 countryChoose a country to see its sites
Registry title
Involvement of the serotonergic system in the control of impulsivity in Tourette disorder : ARITEP
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
5 Sept 2024
Expected to end
1 Oct 2028
Type of study
Interventional
Record updated
29 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Tourette disorder who are about to start aripiprazole in routine care. It uses PET and fMRI brain scans to study impulsivity.

Age
18-65 years
Sex
Men and women can join.
Disease stage
Tourette disorder diagnosed by DSM-5 criteria, with tics that still allow PET and fMRI scans.
Earlier treatment
Treatment with aripiprazole must already be planned. People taking drugs with serotonergic effects (for example amphetamine, cocaine, MDMA, SSRIs, mianserin) cannot join.

Main reasons for not taking part

  • A serious, uncontrolled psychiatric illness, or a serious, worsening or disabling illness that could affect the study
  • Cannot have fMRI or PET scans (for example pacemaker, metal implant, fear of closed spaces)
  • Breastfeeding women; women must use effective birth control
  • Took part in a study with radiation or radioactive tracers in the past year, or in another study now
  • Not covered by French social security, or does not speak French

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Male or Female
  • Diagnosed with a Tourette Disorder following the DSM-5
  • Age between 18-65 years
  • Member of a social security scheme in France
  • Freely-given informed consent to participate to this study (written form)
  • With a current treatment by aripiprazole already scheduled
  • With Tics compatible with TEP/fMRI exams
  • Having (for women only) effective contraception throughout participation in the study

Who cannot take part

  • Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin)
  • Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia)
  • Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study
  • A serious not controlled psychiatric comorbidity
  • Male or Female
  • A serious, evolving or debilitating pathology with a potential influence on the study
  • Women breastfeeding
  • Protected or restricted person (administratively or in judicial terms)
  • Do not speak french

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine the correlative links between the availability of serotonergic 5-HT2A receptors and the variations in impulsivity measured in adults with Tourette's syndrome during treatment begin in the routine care.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Involvement of the serotonergic system in the control of impulsivity in Tourette disorder : ARITEP
Plain-language title
Serotonin receptors and impulsivity in adults with Tourette syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
29 June 2026
Involvement of the serotonergic system in the control of impulsivity in Tourette disorder : ARITEP (2023-506370-13-00) – Frontlight Research